Core Viewpoint - The announcement from Beijing Kangchen Pharmaceutical Co., Ltd. highlights the recent abnormal fluctuations in its stock price and reassures investors about the company's stable operational status while urging caution in trading activities [1][2]. Group 1: Production and Operational Status - The company confirms that its production and operational activities are normal, with no significant changes or undisclosed major events apart from previously disclosed information [1]. Group 2: Stock Market Trading Risks - The company's stock experienced a cumulative price increase deviation of over 20% across three consecutive trading days (July 9, 10, and 11, 2025), indicating abnormal trading activity [1]. - On July 14, 2025, the company's stock hit the daily limit up again, reflecting significant short-term price increases, prompting a warning for investors to be mindful of trading risks [1]. Group 3: Other Risks and Developments - The company has secured exclusive rights for clinical development and commercialization of Ensifentrine (Ohtuvayre™) in Greater China, a novel drug for treating chronic obstructive pulmonary disease (COPD) [2]. - Merck announced the acquisition of Verona Pharma for approximately $10 billion on July 9, 2025, which may impact the market landscape [2]. - The company's subsidiary holds a 4.96% stake in Nuance Biotech, which has not been profitable in the past five years, indicating that this investment is unlikely to significantly affect the company's overall performance [2].

Core Viewpoint - Beijing Kangchen Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price deviation exceeding 20% over three consecutive trading days from July 9 to July 11, 2025, indicating abnormal trading activity [1][2]. Group 1: Stock Trading Abnormalities - The company's stock price increased significantly, with a cumulative closing price deviation exceeding 20% over three consecutive trading days [1]. - The company conducted a self-examination and confirmed that there were no undisclosed significant information related to the stock price fluctuations [2]. Group 2: Business Operations - The company's production and operational activities are reported to be normal, with no significant changes in daily operations [1]. - There are no major undisclosed events such as asset restructuring, stock issuance, or significant business collaborations that could impact the stock price [2]. Group 3: Sensitive Information - During the period of stock price fluctuation, company executives and major shareholders did not engage in buying or selling the company's stock [2]. - The company holds a 4.96% stake in Nuance Biotech and has exclusive rights for the clinical development and commercialization of Ensifentrine in Greater China, valued at approximately $10 billion [2].